Table 1.
Baseline features of enrolled patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma.
| Features | HTP-CT Arm | CT Arm | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pat. 1 | Pat. 2 | Pat. 3 | Pat. 4 | Pat. 5 | Median (Range) |
Pat. 1 | Pat. 2 | Pat. 3 | Pat. 4 | Pat. 5 | Median (Range) |
p-Value | |
| Sex, M/F, n (%) | M | M | F | F | F | - | M | M | F | M | F | - | 0.55 |
| Age (years) | 68 | 73 | 77 | 61 | 74 | 64 (61–68) |
67 | 54 | 57 | 65 | 59 | 59 (54–67) |
0.21 |
| Tumor site, H/B/T, n (%) | H | B | H | B | B | - | B | H | B | H | H | - | 0.55 |
| Tumor size (mm) at MDCT | |||||||||||||
| -short axis | 20.3 | 34.1 | 29.9 | 42.7 | 22.1 | 29.9 (20.3–42.7) |
64.5 | 21.9 | 29.7 | 34.7 | 33 | 33 (21.9–65.5) |
0.60 |
| -long axis | 33.8 | 58 | 44.7 | 50.1 | 32.3 | 44.7 (32.3–58) |
95.4 | 29.3 | 37.4 | 49.9 | 44.7 | 44.7 (29.3–95.4) |
1.00 |
| Tumor volume (cc) at MDCT | 12.14 | 31.34 | 25.29 | 35.97 | 10.15 | 25.3 (10.1–36) |
101.4 | 5.3 | 16.85 | 29.4 | 21.8 | 21.8 (5.3–101.4) |
0.92 |
| Tumor staging, BR/LA, n (%) | BR | LA | LA | LA | LA | - | LA | LA | LA | LA | BR | - | 1.00 |
| CA19.9 serum levels (U/mL) | 362 | 2495 | 43 | 602 | 281 | 362 (43–2495) |
3503 | 243.8 | 361 | 5192 | 20 |
361 (20–5192) |
0.92 |
| WBC serum levels (109/L) | 7.7 | 7.45 | 9.9 | 6.8 | 9.1 | 7.7 (6.8–9.9) |
11.5 | 7.46 | 6.7 | 9.9 | 7.6 | 7.9 (6.7–11.5) |
0.69 |
| PLT serum levels (109/L) | 316 | 215 | 253 | 259 | 361 | 259 (215–361) |
213 | 255 | 288 | 256 | 188 | 255 (188–325) |
0.23 |
| Neutrophils serum levels (109/L) | 4.9 | 3.99 | 6.5 | 4.6 | 6.7 | 4.9 (3.99–6.7) |
8.4 | 5.63 | 2 | 6.3 | 4.3 | 4.6 (2–8.4) |
0.99 |
| Lymphocytes serum levels (109/L) | 1.9 | 1.99 | 2.5 | 1.5 | 1.6 | 1.5 (1.9–2.5) |
2.1 | 1.2 | 3.2 | 2.3 | 2.1 |
2.15 (1.2–3.2) |
0.46 |
| Monocytes serum levels (109/L) | 0.6 | 0.83 | 0.8 | 0.6 | 0.7 | 0.7 (0.6–0.8) |
0.8 | 0.54 | 0.5 | 0.9 | 0.8 | 0.65 (0.5–0.9) |
0.98 |
| Neutrophil/Lymphocyte ratio | 2.58 | 2.01 | 2.6 | 3.07 | 4.19 | 2.6 (2–4.19) |
4 | 4.69 | 0.625 | 2.74 | 2.05 | 2.74 (0.62–4.69) |
0.92 |
| PLT/Lymphocyte ratio | 166.32 | 108.04 | 101.2 | 172.67 | 225.63 | 166.3 (101–226) |
101.43 | 212.5 | 90 | 111.3 | 89.52 | 101.43 (90–212.5) |
0.17 |
| Lymphocyte/Monocyte ratio | 3.17 | 2.397 | 3.13 | 2.5 | 2.29 | 2.5 (2.29–3.17) |
2.625 | 2.22 | 6.4 | 2.56 | 2.62 | 2.62 (2.22–6.4) |
0.75 |
HTP-CT: HybridTherm Probe ablation and chemotherapy; CT: Chemotherapy; M: males; F: females; H: pancreatic head; B: pancreatic body; T: pancreatic tail; MDCT: multidetector computed-tomography scan; BR: borderline resectable; LA: locally advanced; WBC: white blood cells; PLT: platelets.